Quantcast

Top Questions From Patients

Answer

SurForce® is a cryopreserved injectable derived from Amniotic Membrane Tissue.

Answer

For patient outcomes and success stories, please contact the SurForce® Healthcare Provider nearest you. You can also peruse through our patient testimonial section here.

Answer

The easiest way to get started is by filling out the contact questionnaire found here. We can identify the nearest SurForce® Providers in your area. A Provider will contact you shortly to address any of your questions or concerns. Surgenex distributes its products exclusively to verified medical facilities.

Answer

Our bodies naturally degenerate over time. The regenerative processes that were once vibrant and energetic in our youth become slower and impeded as we age.

Answer

Your Provider may or may not recommend post-treatment rehabilitation. This decision will depend heavily upon the injured area and its pathology/etiology, as well as your current physical health status. Patients should work with their Healthcare Provider to determine if rehab will be necessary and/or beneficial.

Answer

Depending on the etiology, pathology, and severity of the chief complaint, each patient will be unique. Healthcare Providers can gather subjective and objective information such as patient history, orthopaedic examinations, diagnostic imaging, and lab results to assess and determine the patient’s needs. Based on these findings, Healthcare Providers can specify an appropriate treatment plan. Costs associated with specific procedures may depend on these variables. For specifics, contacting the nearest Provider of SurForce® for a consultation is recommended.

Answer

Depending on the region, or if there are multiple locations needing an injection, the treatment procedure can be administered during a standard office visit. Specific times may vary depending on factors inherent to the complications of the patient’s needs. The application of the treatment is non-surgical, and requires no pre-treatment preparation time.

Answer

There are several advantages to using Amniotic Membrane tissues rather than invasive medical procedures. Unlike pharmaceuticals and lengthy surgical procedures, to date no negative side effects have been reported with amniotic membrane allografts.

Answer

As with any treatment modality in Healthcare, there is always an inherent risk. It is understood from the research, that no adverse side effects are evident. Furthermore, SurForce® maintains the highest standards of safety in our industry, exceeding the FDA’s minimum safety requirements.

Answer

Surgenex uses the Excellion® Process to produce SurForce®. This patent-pending process is a highly manual and surgical process that isolates the amniotic membrane layer of the placenta. No other portion of the placenta is utilized.

Answer

Research shows that amniotic membrane tissue allografts contain extracellular matrices including growth factors, anti-fibrotics , anti-microbials, are immune-evasive, and have anti-inflammatory properties.

Research also shows it has the potential to repair articular cartilage. Please peruse our Research section here for research articles related to the incredible benefits of amniotic membrane tissue allografts.

Top questions from providers

Answer

We hold ourselves to a higher standard to perform above and beyond the minimum requirements in the industry, ensuring best practices and superior product outcomes. SurForce has been tested for relevant communicable diseases in accordance with the required FDA standards for tissue donation. Additionally, our donor serology test panel is the most extensive in the industry, testing for several potential pathogens that could be missed by less extensive testing observed in competitive industry products. SURGENEX® conducts a 14-day bacterial/fungal test performed by a third-party lab, to confirm our products are free of bacterial and fungal contaminants. These two safety barriers verify that SurForce® is the cleanest and safest amniotic membrane tissue allograft product on the market.

Answer

SurForce® is an amniotic membrane injectable categorized as Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/P’s) under Section 361. Currently, the FDA regulates all biological regenerative products under this Section. Moreover, under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR part 493, all contracted laboratories performing human specimen tests are certified and meet the requirements as determined by the Centers for Medicare and Medicaid Services (CMS). SURGENEX® is current in the FDA Establishment Registration and Listing of Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/P).

Answer

Donor eligibility requirements are set forth and regulated by the FDA to ensure the Donor of the Placental tissue for transplantation is free of specific infectious and communicable diseases. Donor recoveries meet and adhere to the regulations requisite to HCT/P recovery. Screening and testing of the tissue donor is verified through laboratory serology test panels. Once all criteria are satisfied, the donor placental tissue is deemed qualified for processing and transplantation

Answer

The FDA requires HCT/P products under section 361 to be traceable in the event of an adverse reaction. Lot tracking is utilized as a course of action for documenting the management and storage of a specimen from donor to collector to the final transplant destination, and the review and reporting of the final results by a Healthcare Provider.

Answer

SURGENEX®, LLC accepts no returns of SurForce®. Although SURGENEX®, LLC has taken great measures to ensure the safety of our allograft product, current technologies cannot preclude the transmission of certain diseases known or unknown, therefore, SURGENEX®, LLC can make no claims concerning the biological properties and safety of allograft tissue. All tissues have been collected, processed, screened, tested, stored, and distributed in compliance with all current FDA regulations concerning HCT/Ps.

Answer

SurForce® is an Amniotic membrane allograft cryopreserved, with highest concentration of amniotic membrane compared to any other products derived from placental tissue. Research shows amniotic membrane contains growth factor components, anti-fibrous functions, anti-microbial properties, immune-evasive properties, pain management and anti-inflammatory properties, as well as the potential to repair articular cartilage. Please peruse our Research section here for research articles related to the incredible benefits of amniotic membrane allograft tissue.

Answer

Autograft is defined as a graft of tissue from one point to another of the same individual's body, simply, a host to host implantation of tissue. Whereas an Allograft is a tissue graft from a donor of the same species as the recipient but not genetically identical, or simply, a Donor to Host Transplantation of tissue.

Answer

We are not entirely sure as to why Autograft companies describe our product as Amniotic fluid, however, the claim is quite misleading and a false equivalent as our product is derived from the amniotic membrane.

Answer

Distribution of SURGENEX® products are cryopreserved and shipped in shipping containers utilizing dry ice to maintain critical low temperatures.

Answer

Our shipping solutions are designed to maintain its ultra-cold temperature integrity for up to 72 hours. Overnight shipping is the standard service that SURGENEX® provides its customer base, however, there are rare occasions in which packages encounter delays in the distribution chain due to inclement weather or mechanical failures of Courier equipment.

Download Product Brochure SurForce®

CRYOPRESERVED AMNIOTIC MEMBRANE ALLOGRAFT Injections

Amniotic membrane has been successfully used in treatments for decades.